Company name:
Teladoc Health Inc
-
IPO SHARE PRICE:$19.00
-
IPO DATE:July 01, 2015
-
TICKER:TDOC
-
MAIN STOCK EXCHANGE:New York Stock Exchange
-
CURRENT HQ LOCATION:2 Manhattanville Road Suite 203 Purchase New York 10577
-
FISCAL YEAR END:December 31
-
INCORPORATION JURISDICTION:DE
-
ORGANIZED AS THE FOLLOWING LEGAL TYPE:Corporation
-
Investor Relations Webpage:Coming soon!
-
TAX RATE:USA federal corporate nominal income tax rate is 21%
Short Description
Teladoc Health Inc
We are working hard and as soon as possible to provide company description soon. Feel free to reach out to request it sooner: improve@real-clear-investing.com
Statement of Cash Flow
(USD in thousand)
Selected Year:
31-Dec
2020
2020
OPERATING ACTIVITIES
Cash received and spent on operating activites of business — buying materials, paying salaries, receiving payments from clients, etc
64.3% -
Stock-based compensation
9.4% -
Depreciation and amortization
6.1% -
Accretion of interest
4.7% -
Accrued compensation and employee benefits
2.7% -
Accrued expenses and other liabilities
2.4% -
Deferred revenue
1.2% -
(Gain) loss on repayment of debt
0.9% -
Amortization of right-of-use assets
0.7% -
(Recovery of) provision for doubtful accounts
0.2% -
Depreciation of rental equipment
SOURCEs
7.2%
9.4%
6.1%
4.7%
64.3%
100 %
0%
USES
12.2%
11.9%
3.3%
65.6%
65.6% -
Net income (loss)
12.2% -
Deferred income taxes
11.9% -
Accounts payable
3.3% -
Inventory
2.9% -
Accounts receivable
1.7% -
Prepaid expenses and other assets
1.1% -
Other assets
0.9% -
Operating lease liabilities
0.3% -
Other liabilities
0.1% -
Change in fair value of contingent consideration
|
|
|
|
|
|
|
|
|
|
|
---|---|---|---|---|---|---|---|---|---|---|
Net income (loss) | ($97,084) | ($98,864) | ($485,136) | ($485,136) | ($1,575,868) | |||||
Depreciation and amortization
|
35,602 | 44,952 | 69,495 | 69,495 | 125,864 | |||||
Depreciation of rental equipment
|
- | - | 1,697 | 1,697 | 6,788 | |||||
Amortization of right-of-use assets
|
- | 6,000 | 6,895 | 6,895 | 27,580 | |||||
Stock-based compensation
|
43,769 | 66,702 | 475,531 | 475,531 | 1,657,520 | |||||
Amortization of warrants
|
- | - | - | - | - | |||||
Amortization of warrants and loss on extinguishment of debt
Amortization of warrants and loss on extinguishment of debt
|
- | - | - | - | - | |||||
(Recovery of) provision for doubtful accounts
|
2,243 | 2,665 | 5,284 | 5,284 | 11,856 | |||||
Accretion of interest
|
19,487 | 25,438 | 45,296 | 45,296 | 63,348 | |||||
Deferred income taxes
|
(2,247) | (10,868) | (90,158) | (90,158) | (344,248) | |||||
Asset impairments
|
- | - | - | - | - | |||||
Gain on sale
|
(5,500) | - | - | - | - | |||||
(Gain) loss on repayment of debt
|
- | - | 9,077 | 9,077 | 396 | |||||
Change in fair value of contingent consideration
|
- | 1,248 | (1,009) | (1,009) | (4,036) | |||||
Accounts receivable
|
(10,931) | (15,884) | (21,091) | (21,091) | (18,564) | |||||
Due from officer
|
- | - | - | - | - | |||||
Inventory
|
- | - | (24,732) | (24,732) | (89,360) | |||||
Prepaid expenses and other assets
|
(2,612) | (2,685) | (12,565) | (12,565) | (26,636) | |||||
Other assets
|
(414) | (105) | (8,135) | (8,135) | (33,100) | |||||
Accounts payable
|
(391) | 905 | (87,995) | (87,995) | (378,316) | |||||
Accrued compensation and employee benefits
|
8,480 | 4,546 | 34,819 | 34,819 | 101,960 | |||||
Accrued expenses and other liabilities
|
3,993 | 14,841 | 20,125 | 20,125 | 11,424 | |||||
Deferred revenue
|
3,539 | 4,815 | 17,751 | 17,751 | 9,612 | |||||
Operating lease liabilities
|
- | (2,417) | (6,300) | (6,300) | (7,760) | |||||
Other liabilities
|
745 | 643 | (2,360) | (2,360) | 1,796 | |||||
Net cash provided by (used in) operating activities | ($4,860) | $29,869 | ($53,511) | ($53,511) | ($459,744) |
Selected Year:
31-Dec
2020
2020
INVESTING ACTIVITIES
Cash spent on acquiring plant, equipment and other businesses, cash recei0 from sale of plant, equipment and subsidiaries as well cash parked temporarily in different securities - government bonds typically
0.4% -
Maturities of marketable securities
SOURCEs
99.6%
100 %
0%
USES
3.7%
95.6%
95.6% -
Acquisition of business net of cash
3.7% -
Capitalized internal-use software development costs
0.7% -
Capital expenditures
|
|
|
|
|
|
|
|
|
|
|
---|---|---|---|---|---|---|---|---|---|---|
Purchases of marketable securities
|
(56,347) | - | - | - | - | |||||
Maturities of marketable securities
|
84,170 | 52,100 | 2,496 | 2,496 | 9,984 | |||||
Purchases of investment securities
|
- | (5,000) | - | - | - | |||||
Capital expenditures
|
(4,011) | (3,510) | (4,024) | (4,024) | (16,096) | |||||
(Purchase) sale of property and equipment
|
(4,011) | (3,510) | - | - | - | |||||
Sale of assets
|
5,530 | - | - | - | - | |||||
Capitalized internal-use software development costs
|
(4,396) | (7,390) | (22,018) | (22,018) | (88,072) | |||||
Purchase of internal-use software
|
(4,396) | (7,390) | - | - | - | |||||
Acquisition of business net of cash
|
(282,442) | (11,187) | (567,429) | (567,429) | (1,631,064) | |||||
Net cash provided by (used in) investing activities | ($257,496) | $25,013 | ($590,975) | ($590,975) | ($1,655,700) |
Selected Year:
31-Dec
2020
2020
FINANCING ACTIVITIES
Items in this group are concerned with borrowing funds, repaying debt, issuing equity, buying back shares, etc.
30.8% -
Sale of capped call related to the Livongo notes
18.3% -
Proceeds from issuance of common stock upon exercise of stock options net of withholding taxes
2.0% -
Proceeds from advances from financing companies
1.6% -
Proceeds (payments) related to employee stock compensation plans (ESPP)
SOURCEs
47.3%
18.3%
30.8%
100 %
0%
USES
9.0%
8.1%
3.4%
76.7%
76.7% -
Repurchase of notes
9.0% -
Cash (paid) received for withholding taxes on stock-based compensation net
8.1% -
Issuance costs of 2027 notes
3.4% -
Repayment of assumed debt
2.9% -
Payment from customers against advances from financing companies
|
|
|
|
|
|
|
|
|
|
|
---|---|---|---|---|---|---|---|---|---|---|
Initial Public Offering (IPO) net
|
- | - | - | - | - | |||||
Issuance of common stock
|
330,843 | - | - | - | - | |||||
Issuance of convertible preferred stock
|
- | - | - | - | - | |||||
Proceeds from issuance of common stock upon exercise of stock options net of withholding taxes
Proceeds from issuance of common stock upon exercise of stock options net of withholding taxes
|
31,322 | 33,283 | 54,314 | 54,314 | 54,748 | |||||
Proceeds from issuance of common stock upon exercise of stock options and warrants
Proceeds from issuance of common stock upon exercise of stock options and warrants
|
- | - | - | - | - | |||||
Proceeds (payments) related to employee stock compensation plans (ESPP)
Proceeds (payments) related to employee stock compensation plans (ESPP)
|
2,564 | 3,380 | 4,722 | 4,722 | 8,996 | |||||
Borrowing (repayment) under Bank Loan
|
- | - | - | - | - | |||||
Borrowing (repayment) under bank overdraft
|
- | - | - | - | - | |||||
Bank and other borrowing
|
10 | - | - | - | - | |||||
Issuance of notes
|
279,152 | - | - | - | 4,000,000 | |||||
Repurchase of notes
|
- | - | (228,153) | (228,153) | (912,612) | |||||
Issuance of Convertible Notes
|
279,152 | - | - | - | - | |||||
Proceeds from advances from financing companies
|
- | - | 6,002 | 6,002 | 16,312 | |||||
Payment from customers against advances from financing companies
Payment from customers against advances from financing companies
|
- | - | (8,635) | (8,635) | (16,832) | |||||
Repayment of debt
|
- | - | - | - | - | |||||
Repayment of assumed debt
|
- | - | (10,000) | (10,000) | (40,000) | |||||
Issuance costs of 2027 notes
|
- | - | (24,070) | (24,070) | - | |||||
Proceeds from cash received for withholding taxes on stock-based compensation net
Proceeds from cash received for withholding taxes on stock-based compensation net
|
1,721 | - | - | - | - | |||||
Cash (paid) received for withholding taxes on stock-based compensation net
Cash (paid) received for withholding taxes on stock-based compensation net
|
1,721 | (1,569) | (26,703) | (26,703) | (108,116) | |||||
Stock repurchases
|
- | - | - | - | - | |||||
Sale of capped call related to the Livongo notes
|
- | - | 91,659 | 91,659 | 366,636 | |||||
Net cash provided by (used in) financing activities | $645,612 | $35,094 | $859,136 | $859,136 | $281,744 |
Selected Year:
31-Dec
2020
2020
NET CHANGE IN CASH
Grand Total for sum of cash flows coming from operations, investing and financing
$214,650,000
|
|
|
|
|
|
|
|
|
|
|
---|---|---|---|---|---|---|---|---|---|---|
Cash and equivalents - Beginning of period | $42,817 | $423,989 | $514,353 | - | $4,749,196 | |||||
Effect of changes in foreign exchange rates on cash | (2,084) | 388 | 4,321 | - | 17,800 | |||||
(Decrease) increase in cash and cash equivalents | 383,256 | 89,976 | 214,650 | - | (1,833,700) | |||||
Cash and equivalents - End of period | $423,989 | $514,353 | $733,324 | - | $2,933,296 |